A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors
NCT #
NCT05076591
Condition(s)
Breast Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Solid Tumor
Molecular Target(s)
CD47, ERBB2
Drug Classification(s)
bispecific antibody
Agents(s)
IMM2902
Phase(s)
I
Mechanism of Action
IMM2902 is a bispecific antibody designed to bind to and block CD47, a cell surface protein that inhibits the immune response, and also bind to ERBB2, a protein found on the cell surface of certain tumors.
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from the study agent
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.